Nanollose Limited (NC6)

Overview

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Founded in 1995 and based in Cambridge, Massachusetts, this company has dedicated its research to discovering and advancing novel medicines, particularly in the oncology field. Infinity Pharmaceuticals has formed strategic alliances with notable industry players like Intellikine, Inc., Verastem, Inc., PellePharm, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company, to bolster its product development and commercialization efforts. Despite its ambitious endeavors in cancer treatment, Infinity Pharmaceuticals filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on September 29, 2023, which was later approved as a Chapter 11 liquidation on March 7, 2024.

Products and Services

Infinity Pharmaceuticals, Inc. has been at the forefront of developing immuno-oncology products, with its research efforts yielding promising candidates like eganelisib (IPI-549). The company's pipeline focuses on addressing the unmet medical needs of cancer patients through innovative therapies. Below is a closer look at Infinity Pharmaceuticals' product candidate and strategic collaborations.

• Eganelisib (IPI-549): This is the company's flagship clinical-stage immuno-oncology candidate, designed to inhibit the phosphoinositide-3-kinase-gamma (PI3K-gamma) enzyme. Its potential effectiveness is being assessed through various clinical trials:
  • Phase 2 clinical trials for treating metastatic triple negative breast cancer and urothelial cancer.
  • Phase 1/1b clinical trials aimed at evaluating its effectiveness in solid tumors.
• Strategic Alliances: Infinity Pharmaceuticals has leveraged partnerships to accelerate its research and development efforts.
  • With Intellikine, Inc., the company aims to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K.
  • Collaboration with Verastem, Inc., focuses on researching, developing, commercializing, and manufacturing duvelisib and products containing duvelisib.
  • An agreement with PellePharm, Inc., to advance and market rights to its hedgehog inhibitor program, particularly the clinical-stage product candidate, IPI-926.
  • Partnerships with industry giants like F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company, further enhance their research capacity and market reach.